| Inflammasomes in neuroinflammatory and neurodegenerative diseases |
80 |
| Tranilast directly targets NLRP3 to treat inflammasome-driven diseases |
62 |
| The role of the microbiome in NAFLD and NASH |
61 |
| A versatile drug delivery system targeting senescent cells |
41 |
| G-quadruplex-binding small molecules ameliorate C9orf72 FTD/ALS pathology in vitro and in vivo |
40 |
| Reprogramming of basic metabolic pathways in microbial sepsis: therapeutic targets at last? |
36 |
| mtDNA heteroplasmy level and copy number indicate disease burden in m.3243A > G mitochondrial disease |
32 |
| Targeting senescent cells in translational medicine |
31 |
| Functional systemic CD4 immunity is required for clinical responses to PD-L1/PD-1 blockade therapy |
31 |
| Amyloid blood biomarker detects Alzheimer's disease |
31 |
| P2X4 receptor controls microglia activation and favors remyelination in autoimmune encephalitis |
31 |
| Dual IRE1 RNase functions dictate glioblastoma development |
29 |
| Cerebrospinal fluid and plasma biomarker trajectories with increasing amyloid deposition in Alzheimer's disease |
28 |
| A RAD51 assay feasible in routine tumor samples calls PARP inhibitor response beyond BRCA mutation |
28 |
| FGF21 gene therapy as treatment for obesity and insulin resistance |
27 |
| Cellular, molecular, and clinical mechanisms of action of deep brain stimulation-a systematic review on established indications and outlook on future developments |
27 |
| Inhibition of Stat3-mediated astrogliosis ameliorates pathology in an Alzheimer's disease model |
26 |
| Detection of cell-free DNA fragmentation and copy number alterations in cerebrospinal fluid from glioma patients |
26 |
| A dual-AAV approach restores fast exocytosis and partially rescues auditory function in deaf otoferlin knock-out mice |
24 |
| The GPR120 agonist TUG-891 promotes metabolic health by stimulating mitochondrial respiration in brown fat |
22 |
| Genetic engineering of hematopoiesis: current stage of clinical translation and future perspectives |
22 |
| Inhibition of DDR1-BCR signalling by nilotinib asanew therapeutic strategy for metastatic colorectal cancer |
21 |
| Modulation of three key innate immune pathways for the most common retinal degenerative diseases |
21 |
| Inhibition of proteasome rescues a pathogenic variant of respiratory chain assembly factor COA7 |
21 |
| A proteomic network approach across the ALS-FTD disease spectrum resolves clinical phenotypes and genetic vulnerability in human brain |
20 |
| Opposite microglial activation stages upon loss of PGRN or TREM2 result in reduced cerebral glucose metabolism |
20 |
| Selective depletion of metastatic stem cells as therapy for human colorectal cancer |
20 |
| Inhibition of Drp1/Fis1 interaction slows progression of amyotrophic lateral sclerosis |
19 |
| USP14 inhibition corrects an in vivo model of impaired mitophagy |
19 |
| Progerin accelerates atherosclerosis by inducing endoplasmic reticulum stress in vascular smooth muscle cells |
18 |
| A circRNA signature predicts postoperative recurrence in stage II/III colon cancer |
18 |
| Salivary glands regenerate after radiation injury through SOX2-mediated secretory cell replacement |
18 |
| Plasma Proteome Profiling to detect and avoid sample-related biases in biomarker studies |
18 |
| OTULIN deficiency in ORAS causes cell type-specific LUBAC degradation, dysregulated TNF signalling and cell death |
18 |
| In vivo generation of human CD19-CAR T cells results in B-cell depletion and signs of cytokine release syndrome |
17 |
| Apelin inhibition prevents resistance and metastasis associated with anti-angiogenic therapy |
17 |
| The BACE-1 inhibitor CNP520 for prevention trials in Alzheimer's disease |
17 |
| Rapamycin rescues mitochondrial myopathy via coordinated activation of autophagy and lysosomal biogenesis |
16 |
| miR-181a/b downregulation exerts a protective action on mitochondrial disease models |
16 |
| Parkin is a disease modifier in the mutant SOD1 mouse model of ALS |
15 |
| D-Aspartate treatment attenuates myelin damage and stimulates myelin repair |
15 |
| Co-targeting BET and MEK as salvage therapy for MAPK and checkpoint inhibitor-resistant melanoma |
15 |
| mitoTev-TALE: a monomeric DNA editing enzyme toreduce mutant mitochondrial DNA levels |
15 |
| Brain-targeted stem cell gene therapy corrects mucopolysaccharidosis type II via multiple mechanisms |
14 |
| From molecular promise to preclinical results: HDAC inhibitors in the race for healthy aging drugs |
14 |
| Fatty acid synthase mediates EGFR palmitoylation in EGFR mutated non-small cell lung cancer |
14 |
| Repeat-associated non-AUG translation in C9orf72-ALS/FTD is driven by neuronal excitation and stress |
14 |
| FoxO3 an important player in fibrogenesis and therapeutic target for idiopathic pulmonary fibrosis |
14 |
| Lipid droplet-dependent fatty acid metabolism controls the immune suppressive phenotype of tumor-associated macrophages |
13 |
| Stromal fibroblast growth factor 2 reduces the efficacy of bromodomain inhibitors in uveal melanoma |
13 |
